Chen Gui-Hua, Lu Min-Qiang, Cai Chang-Jie, Yang Yang, He Xiao-Shun, Zhu Xiao-Feng
Transplantation Surgery, the Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510630, China.
Zhonghua Wai Ke Za Zhi. 2004 Sep 7;42(17):1040-3.
To investigate the effect of adjuvant individualized chemotherapy in prevention of tumor recurrence and improvement of patient survival after liver transplantation for hepatocellular carcinoma (HCC).
21 HCC cases received orthotopic liver transplantation and treated with adjuvant individualized chemotherapy based on ATP tumor chemosensitivity assay (ex vivo) between April 2001 and January 2003 were retrospective reviewed, compared with 52 cases received orthotopic liver transplantation only. The cumulative and tumor-free survivals were compared between 2 groups.
The 1, 2 years overall survival rates were 92.31%, 73.85% for the individualized chemotherapy group and 92.06%, 63.93% for the non-chemotherapy group, the difference was not statistically significant. The 6, 12, 18, 24 months tumor-free survival rates were 90.00%, 80.00%, 80.00%, 60.00% and 67.31%, 51.92%, 40.03%, 37.81% respectively, the difference was statistically significant (P <0.05).
This study suggests that tumor recurrence decreases and tumor-free survival increases by adjuvant individualized chemotherapy after liver transplantation for HCC. The individualized protocol based on ATP-TCA may be effective for patients with HCC after liver transplantation.
探讨辅助性个体化化疗对预防肝细胞癌（HCC）肝移植术后肿瘤复发及提高患者生存率的作用。
回顾性分析2001年4月至2003年1月间21例行原位肝移植并基于ATP肿瘤药敏试验（体外）接受辅助性个体化化疗的HCC病例，并与52例仅接受原位肝移植的病例进行比较。比较两组的累积生存率和无瘤生存率。
个体化化疗组1年、2年总生存率分别为92.31%、73.85%，非化疗组为92.06%、63.93%，差异无统计学意义。6个月、12个月、18个月、24个月无瘤生存率分别为90.00%、80.00%、80.00%、60.00%和67.31%、51.92%、40.03%、37.81%，差异有统计学意义（P<0.05）。
本研究表明，HCC肝移植术后辅助性个体化化疗可降低肿瘤复发率，提高无瘤生存率。基于ATP-TCA的个体化方案可能对HCC肝移植术后患者有效。
Zotero 插件